US Patent
US12458634 — Stabilized liquid formations containing picosulfate
Formulation · Assigned to Ferring BV · Expires 2038-01-27 · 12y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects stabilized liquid oral formulations containing sodium picosulfate, magnesium citrate, citric acid, malic acid, and an antioxidant.
USPTO Abstract
Oral liquid formulations are provided containing sodium picosulfate, magnesium citrate, citric acid, malic acid, and an antioxidant selected from potassium metabisulfite and sodium metabisulfite, wherein the antioxidant is present in the composition at a concentration of from about 0.002 M to about 0.1 M, and wherein the composition has a pH of from about 4.0 to about 6.5.
Drugs covered by this patent
- Renacidin (CITRIC ACID) · Baxter
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.